Baxalta in
talks to buy
U.S. hematology-oncology specialist ? Bloomberg
Aug 28 (Reuters) - Drugmaker
Baxalta Inc is working with bankers to buy a U.S.-based hematology and oncology
specialist valued at about $2 billion,
Bloomberg reported, citing people familiar with the...
